Department of Cardiac and Thoracic Surgery, RWTH Aachen University Clinic, Pauwelstr. 31, Aachen, 52074, Germany.
Department of Orthopaedics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Int J Clin Pharm. 2021 Jun;43(3):449-460. doi: 10.1007/s11096-020-01166-2. Epub 2020 Oct 12.
Background Little is known with regards to the prognostic factors for patients with suspected or diagnosed Heparin-Induced Thromobocytopenia (HIT). The role of patient and therapy characteristics may play a role in predicting the outcome. Aim of the review To investigate the role of patient and therapy characteristics as potential prognostic factors for HIT-related complications (haemorrhagic and thromboembolic events), and mortality. Method The present systematic review was conducted according to the PRISMA statement. In September 2020, the main online databases were accessed: Pubmed, EMBASE, Scopus, Google Scholar. All the clinical trials concerning the management of patients with suspected or confirmed HIT were eligible. Studies evaluating the use of oral anticoagulants (e.g. vitamin K antagonists, Apixaban) were not considered, along with those comparing the use of heparin. For pairwise correlation, the Pearson Product-Moment Correlation Coefficient (r) was used. The final effect was evaluated according to the Cauchy-Schwarz inequality.Results Data from 33 clinical studies (4338 patients) were retrieved. The overall mean age was 62.3 ± 6.6 years old. Patients with HIT-related thromboembolism at the moment of diagnosis were associated with greater rate of haemorrhages (P > 0.0001), thromboembolism (P > 0.0001) and mortality (P = 0.001). Patients with more comorbidities at diagnosis were associated with a greater risk of haemorrhages (P = 0.07), thromboembolism (P = 0.002) and mortality (P = 0.002). Patients with longer duration of the therapy were associated with lower rate of mortality (P = 0.04). ConclusionsPatient comorbidities, presence of HIT-related thromboembolism on admission and shorter anticoagulant therapy were found to be negative prognostic factors. Thrombocythemia on admission, patients age and gender did not influence the overall outcome.
对于疑似或确诊肝素诱导血小板减少症(HIT)的患者,其预后因素知之甚少。患者和治疗特点可能在预测结局方面发挥作用。本综述的目的:调查患者和治疗特点作为 HIT 相关并发症(出血和血栓栓塞事件)和死亡率的潜在预后因素的作用。方法:本系统综述按照 PRISMA 声明进行。2020 年 9 月,检索了主要在线数据库:PubMed、EMBASE、Scopus、Google Scholar。所有关于疑似或确诊 HIT 患者管理的临床试验均符合入选标准。未考虑评估口服抗凝剂(如维生素 K 拮抗剂、阿哌沙班)使用的研究,也未考虑比较肝素使用的研究。对于成对相关性,使用 Pearson 积矩相关系数(r)。根据柯西-施瓦茨不等式评估最终效果。结果:共检索到 33 项临床研究(4338 例患者)的数据。总体平均年龄为 62.3 ± 6.6 岁。诊断时伴有 HIT 相关血栓栓塞的患者出血(P > 0.0001)、血栓栓塞(P > 0.0001)和死亡率(P = 0.001)的发生率更高。诊断时合并症较多的患者出血(P = 0.07)、血栓栓塞(P = 0.002)和死亡率(P = 0.002)的风险更高。治疗时间较长的患者死亡率较低(P = 0.04)。结论:患者合并症、入院时存在 HIT 相关血栓栓塞以及抗凝治疗时间较短是负性预后因素。入院时血小板增多、患者年龄和性别不影响总体结局。